<DOC>
	<DOC>NCT02337764</DOC>
	<brief_summary>The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.</brief_summary>
	<brief_title>A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants</brief_title>
	<detailed_description>This is a multicenter, open-label, long-term, phase 3 study to evaluate the safety and efficacy of long-term administration of TVP-1012 at 1 mg with levodopa in Japanese participants with Parkinson's disease. The study period will consist of a 2-week screening period and a subsequent 52-week treatment period. Participants fulfilling the inclusion criteria and do not meet any of the exclusion criteria at the start of the screening period (Week -2; Visit1) and also at the end of the screening period (Week 0; Visit 2) will be enrolled in the study, and will receive 1 mg of TVP-1012 once daily for 52 weeks, in an unblinded manner, from the day after Visit 2.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank. The participant has received a levodopa combination drug for &gt;= 1 month and has either of the following. Wearing off phenomenon Decreased response to levodopa combination drugs The participant has received a levodopa combination drug without change in the dose regimen. The participant is an outpatient of either sex aged &gt;= 30 and &lt; 80 years. The participant has Modified Hoehn &amp; Yahr stage 5 (or stage 5 at eather ontime or offtime for the participant with wearing off phenomenon). The participant has severe dyskinesia. The participant has unstable systemic disease. The participant has a MiniMental State Examinations (MMSE) score of &lt;= 24. psychiatric disease. The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyraminerich food. The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation). The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days. The participant has received levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for &gt;= 14 days may be included in the study. The participant is required to take any of the excluded medications or treatments. The participant with laboratory data meeting any of the following: Creatinine &gt;= 2 x upper limit of normal (ULN) Total bilirubin &gt;= 2 x ULN ALT or AST &gt;= 1.5 x ULN ALP &gt;= 3 x ULN The participant has received any of the excluded medications or treatments during.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>